Abstracts tagged "registry and rheumatoid arthritis (RA)"

Abstract Number: 1389 • 2019 ACR/ARP Annual Meeting
Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry
Xue Han¹, Joshua Bryson ¹, David C Crosby ¹, Michael Evans ² and Gabriela Schmajuk ³, ¹Bristol-Myers Squibb, Princeton, ²University of California San Francisco, San Francisco, ³UCSF, SFVAMC Division of Rheumatology, San Francisco, CA
Background/Purpose: ACR guidelines recommend treatment for patients with RA based on baseline (BL) disease activity. In patients with an inadequate response to conventional synthetic DMARDs,…
Abstract Number: 213 • 2018 ACR/ARHP Annual Meeting
Excessive Risk of Major Cardiovascular Events in Sero-Positive Rheumatoid Arthritis and in Patients with Active Disease
Annette de Thurah^1,2, Ina Trolle Andersen³, Andreas Bugge Tingaard⁴, Josephine Therkildsen⁵, Anders Hammerich Riis³, Morten Böttcher⁵ and Ellen-Margrethe Hauge^6,7, ¹Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ²Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, ³Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁵Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁶Department of Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁷Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for the development of cardiovascular disease (CVD). However, the influence of RA on the prognosis after…
Abstract Number: 541 • 2018 ACR/ARHP Annual Meeting
Prevalence of Sjögren’s Syndrome in Patients with RA Enrolled in a Large Observational US Registry
Leslie R Harrold¹, Ying Shan², Sabrina Rebello², Neil Kramer³, Sean E. Connolly⁴, Evo Alemao⁴, Sheila Kelly⁴, Tammy Curtice⁴, Joel Kremer⁵ and Elliot Rosenstein³, ¹University of Massachusetts, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Overlook Medical Center, Institute for Rheumatic & Autoimmune Diseases, Summit, NJ, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Sjögren’s syndrome is a known co-existing autoimmune disease in patients with RA, but its prevalence and impact on RA are poorly understood. The aims…
Abstract Number: 624 • 2018 ACR/ARHP Annual Meeting
Easy Accessibility of Biologics and Its Impact on Disease Activity and Quality of Life in Kuwaiti Patients with Rheumatoid Arthritis
Adeeba Al-Herz¹, Khulood Saleh², Adel Al-Awadhi³, Waleed Al-Kandari², Eman Hasan⁴, Aqeel Ghanem⁵, Yaser Ali⁵, Hebah Alhajeri⁶, Sawsan Hayat⁵, Ali Aldei⁷, Mohammad Hussain⁴, Ibrahim Nahar⁵, Fatemah Abutiban⁸, Ahmad Alenizi⁸, Khaled Mokaddem¹, Ahmad Khadrawy², Ammad Fazal², Agaz Zaman⁵, Ghada Mazloum⁵, Youssef Bartella¹, Sally Hamed¹, Ramia Alsouk⁸ and Ahmed Al-Saber⁹, ¹Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, ²Rheumatology, Farwania Hospital, Farwania, Kuwait, ³Faculty of Medicine, Kuwait, Kuwait, ⁴Al-Amiri Hospital, Kuwait city, Kuwait, ⁵Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ⁶Division of Rheumatology, Mubarak Al-Kabeer Hospital, hawalli, Kuwait, ⁷Rheumatology, Al-Amiri Hospital, Kuwait City, Kuwait, ⁸Rheumatology, Jahra Hospital, Jahra, Kuwait, ⁹Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait
Background/Purpose: Prescribing biologics for patients with rheumatoid arthritis (RA) may be restricted by many factors other than the physician’s clinical judgment. In Kuwait, patients with…
Abstract Number: 1457 • 2018 ACR/ARHP Annual Meeting
Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
Peter M. ten Klooster^1,2, Laura M.M. Steunebrink³, Letty Versteeg⁴, Inmaculada de la Torre⁵, Francesco de Leonardis⁶, Walid Fakhouri⁶, Liliana Zaremba-Pechmann⁶ and Mart van de Laar^1,3, ¹Transparency in Healthcare B.V., Hengelo, Netherlands, ²Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ³Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁴Rheumatology, Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, ⁵Eli Lilly and Company, Madrid, Spain, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Recent studies suggested a disconnect between disease activity and radiographic damage in rheumatoid arthritis (RA) patients treated with more aggressive treatment (1). Therefore, the…
Abstract Number: 1542 • 2018 ACR/ARHP Annual Meeting
Real-World Data from a Post-Approval Safety Surveillance Study of Tofacitinib Vs Biologic Dmards and Conventional Synthetic Dmards: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Joel Kremer¹, Laura C. Cappelli², Carol J. Etzel³, Jeffrey Greenberg³, Jamie Geier⁴, Ann Madsen⁴, Connie Chen⁴, Alina Onofrei³, Christine J Barr³, Dimitrios A. Pappas³, Kimberly J Dandreo³, Andrea Shapiro⁵, Carol A Connell⁶ and Arthur Kavanaugh⁷, ¹Albany Medical College and the Center for Rheumatology, Albany, NY, ²Johns Hopkins University, Baltimore, MD, ³Corrona LLC, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Peapack, NJ, ⁶Pfizer Inc, Groton, CT, ⁷University of California, San Diego School of Medicine, La Jolla, San Diego, CA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A prospective observational 5-year study, embedded within the US Corrona RA registry,…
Abstract Number: 1917 • 2018 ACR/ARHP Annual Meeting
Physician Opioid Prescribing Patterns and Risk for Chronic Opioid Use Among Rheumatoid Arthritis Patients
Yvonne C. Lee¹, Bing Lu², Hongshu Guan³, Jeffrey Greenberg⁴, Joel Kremer⁵ and Daniel Solomon⁶, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Rheumatology Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Corrona, LLC, Waltham, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Experts have implicated physician prescribing rates as a contributing factor to the opioid crisis. However, little is known about heterogeneity in these patterns and…
Abstract Number: 2133 • 2018 ACR/ARHP Annual Meeting
Comparative Disease Burden of Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data from the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Philip J. Mease¹, Mei Liu², Sabrina Rebello³, Hyungjoo Kang², Yujin Park⁴ and Jeffrey Greenberg^2,5, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are 3 common inflammatory rheumatic diseases that can lead to deformities and joint destruction;…
Abstract Number: 2480 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Outcome Measures Used in Rheumatoid Arthritis Cohorts and Registries Around the World: An Environmental Scan from the Outcome Measures in Rheumatology Critical Outcomes in Longitudinal Observational Studies Working Group
Richard Zogala¹, Karla Criner², Maria A. Lopez-Olivo¹, Natalia Zamora³, Devesh Rai¹, Gregory Pratt⁴, Jude K. A. des Bordes¹, Robin Christensen⁵ and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Internal Medicine, Baylor College of Medicine, Houston, TX, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of Rheumatology, Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, & Department of Rheumatology, Odense University Hospital, Copenhagen, Denmark
Background/Purpose: International registries and cohorts could potentially provide long-term data on patient-centered outcomes. In recent years there has been a concerted effort to define a…
Abstract Number: 2486 • 2018 ACR/ARHP Annual Meeting
Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry
Jeffrey R. Curtis¹, J. Lynn Palmer², George W. Reed³, Jeffrey Greenberg⁴, Dimitrios A. Pappas⁵, Leslie R Harrold⁶ and Joel Kremer⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Corrona Research Foundation, Albany, NY, ³UMass Medical School, Worcester, MA, ⁴Corrona LLC, Waltham, MA, ⁵Columbia University, New York, NY, ⁶University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Despite several randomized controlled trials showing comparable clinical outcomes with triple therapy (Triple; MTX, SSZ, HCQ) versus combination therapy with MTX+TNFi (TNFi Combo), the…
Abstract Number: 545 • 2017 ACR/ARHP Annual Meeting
Incidence of Infusion Reactions to Intravenous Golimumab: Results from a Prospective, Real-World Community Registry
Rafat Faraawi¹, Andrew Chow², Majed M M Khraishi³, Derek Haaland⁴, Milton F. Baker⁵, Cathy Tkaczyk⁶, Allen J Lehman⁷, Francois Nantel⁶ and Brendan Osborne⁶, ¹McMaster University, Hamilton, ON, Canada, ²Credit Valley Rheumatology, Mississauga, ON, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St John's, NF, Canada, ⁴Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ⁵VIHA, Victoria, BC, Canada, ⁶Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁷Janssen Inc., Toronto, ON, Canada
Background/Purpose: Golimumab (GLM) is a monoclonal antibody targeting TNF-alpha, indicated for the treatment of adults with rheumatoid arthritis in combination with methotrexate (MTX). GLM-IV is…
Abstract Number: 631 • 2017 ACR/ARHP Annual Meeting
Predictors of Long-Term Retention of Methotrexate and Other Dmards with Golimumab in Rheumatoid Arthritis and Psoriatic Arthritis: An Analysis from a Prospective, Observational Registry
Derek Haaland¹, Anna Jaroszynska², B Haraoui³, Suneil Kapur⁴, Jacqueline Stewart⁵, Wojciech Olsynzynski⁶, Keltie Anderson⁷, Raman Rai⁸, Michael Starr⁹, Alexander Tsoukas¹⁰, Eliofotisti Psaradellis¹¹, Emmanouil Rampakakis¹¹, Cathy Tkaczyk¹², Allen J Lehman¹³, Francois Nantel¹² and Brendan Osborne¹², ¹Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ²Private practice, Burlington, ON, Canada, ³Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁴University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁵Penticton Regional Hospital, Penticton, BC, Canada, ⁶University of Saskatchewan, Saskatoon, ON, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Private Practice, Hamilton, ON, Canada, ⁹Rheumatology, McGill University, Pointe-Claire,, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that concomitant methotrexate therapy may increase the efficacy of biologic treatments. A scarcity of data exists on the benefits of…
Abstract Number: 992 • 2017 ACR/ARHP Annual Meeting
The Effect of Anti-TNF Therapy on Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis over One Year – Real Life Data from the Czech Biologics Registry Attra
Jakub Zavada¹, Lenka Szczukova², Karel Pavelka³ and Jiri Vencovsky³, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Biostatistics and Analyses. Faculty of Medicine, Masaryk University, Brno, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: The ATTRA registry captures more than 95% of patients with RA, PSA or AS treated with biologics in the Czech Republic (CZ). In CZ,…
Abstract Number: 1422 • 2017 ACR/ARHP Annual Meeting
Impact of Adalimumab on Prednisone Use in Patients with Rheumatoid Arthritis in a Real World Setting – Results from the Corrona Registry
Dimitrios A. Pappas¹, Chitra Karki¹, Heather J. Litman¹, Taylor Blachley¹, Jessica L. Suboticki², Jenny Griffith³ and Joel Kremer⁴, ¹Corrona, LLC, Southborough, MA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Steroids are used to reduce inflammation and pain among rheumatoid arthritis (RA) patients, but they can cause harmful side effects, and in some patients,…
Abstract Number: 1815 • 2017 ACR/ARHP Annual Meeting
Patterns of Methotrexate Use and Discontinuation in a U.S. Rheumatoid Arthritis Registry
Jeffrey R. Curtis¹, Gene Wallenstein², Liza Takiya³, David Gruben², Connie Chen⁴, Ying Shan⁵, Taylor Blachley⁵, Kimberly J Dandreo⁵ and Joel Kremer⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, New York, NY, ⁵Corrona, LLC, Southborough, MA, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Methotrexate (MTX) remains a cornerstone therapy in the management of rheumatoid arthritis (RA), but patterns of adherence, intolerance, and inadequate response are not well…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].